<DOC>
	<DOCNO>NCT01887561</DOCNO>
	<brief_summary>The purpose study ass whether dasatinib discontinue without occurrence molecular relapse patient chronic myeloid leukemia chronic phase complete molecular remission ( CMR ) dasatinib .</brief_summary>
	<brief_title>Dasatinib Patients Achieving Complete Molecular Response Cure D-NewS Trial</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Newly diagnose Chronic Myeloid Leukemia Chronic Phase 15 year old . ECOG performance status ( PS ) score 02 . Adequate organ function ( hepatic , renal lung ) . Signed write informed consent . A case double cancer activity . Women pregnant breastfeeding . female patient intention appropriate sterilization , use study entry period Patients complication history severe uncontrolled cardiovascular failure follow Myocardial infarction within 6 month Angina within 3 month Congestive heart failure within 3 month QTc interval 450msec baseline A serious uncontrolled medical disorder would impair ability subject receive protocol therapy</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>